Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change

　　1.Clinical Problem and Setting

　　Gliomas require long-term imaging follow-up after surgery,radiotherapy,and chemotherapy.Treatment can cause blood–brain barrier disruption,inflammation,edema,pseudoprogression,or radiation necrosis.These appear on contrast MRI as new or expanding enhancement that overlaps with true recurrence or progression,so structural imaging alone is often inconclusive.

　　Misclassifying recurrence as treatment effect may delay reoperation,systemic change,or trial enrollment;misclassifying pseudoprogression or necrosis as recurrence may lead to unnecessary biopsy or therapy.Amino-acid PET adds metabolic information to structural findings.

　　2.Drug and Mechanism

　　Pixclara,generic name floretyrosine F-18,also called 18F-FET,is developed by Telix Pharmaceuticals(code TLX101-Px)as an intravenous radioactive diagnostic amino-acid analogue.It enters cells through LAT1 and LAT2 amino-acid transporters;proliferating glioma cells often upregulate these transporters,producing higher tumor uptake than normal brain.

　　Compared with FDG-PET,FET is less affected by high physiologic glucose metabolism in normal brain;compared with 11C-MET,F-18 has a longer half-life and can be distributed from central pharmacies without an on-site cyclotron.The agent is not therapeutic—it maps amino-acid metabolism for PET reconstruction and reader interpretation.

　　3.Approval and Eligible Population

　　The FDA approved Pixclara on 14 September 2026 for use with PET to evaluate recurrent or progressive glioma versus treatment-related brain changes in adults and children aged 1 month and older.Orphan drug and fast track designations supported development.

　　Typical uses:

　　New,enlarged,or ambiguous contrast-enhancing MRI lesions where recurrence versus treatment effect must be separated;

　　High-grade glioma follow-up to distinguish pseudoprogression,radiation necrosis,and true progression;

　　Low-grade glioma with intact or mildly disrupted blood–brain barrier,as an MRI adjunct but not for standalone classification;

　　Pediatric glioma with uncertain imaging,reviewed by pediatric neuro-oncology,nuclear medicine,and neurosurgery.

　　Not appropriate as the sole basis for confirming recurrence,replacing pathology,or making treatment decisions without correlated PET/MRI and clinical context.

　　4.Evidence and Interpretation

　　Approval evidence included two reader-consistency studies in about 381 subjects aged 5–85 years;independent readers classified PET findings as disease progression/recurrence or treatment-related change and were compared with expert conclusions based on MRI,pathology,and clinical follow-up.Reader agreement for disease classification was about 66%–83%and for treatment-related change about 48%–64%;headache occurred in at least 0.5%of subjects.

　　Evidence-based positioning:

　　High-grade glioma:pooled FET-PET sensitivity for true progression versus treatment change is about 0.88 and specificity about 0.78;combined with MRI improves overall judgment;

　　Dynamic FET parameters and tumor-to-background ratio(TBRmax)support boundary assessment—high-grade references often use TBRmax about 2.0–2.3,low-grade thresholds lower;

　　Pseudoprogression often appears within 3 months after chemoradiotherapy;radiation necrosis may appear months to years after radiotherapy—timing alone never confirms or excludes either diagnosis;

　　Reports should state uptake extent,maximum TBR,dynamic curve pattern,spatial relation to enhancing/non-enhancing MRI regions,and a recommendation for histology or follow-up.

　　5.Safety and Workflow

　　Pixclara is short-lived and handled under nuclear-medicine radiation protection;injected activity is set by institution protocol,age,weight,and PET system.Key points:

　　Radiation:F-18 half-life is about 110 minutes;apply post-injection contact,isolation,and excretion precautions per department policy;

　　Adverse events:overall infrequent;headache≥0.5%in safety data,with anaphylaxis managed per radiopharmaceutical protocols;

　　Special groups:children from 1 month need weight-based activity,immobilization,and sedation assessment;defer or substitute in pregnancy/lactation per positron-agent principles;

　　Closed loop:combine PET,co-registered MRI,treatment timeline(surgery/radiotherapy/temozolomide/other),and molecular pathology(IDH,MGMT,1p/19q)in a neuro-oncology multidisciplinary conference.